The Swedish biotechnology company BioLamina was the first actor to run their project at Testa Center. BioLamina was founded in 2008 by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason, and today the company has grown into a business with global presence and about 20 employees.
BioLamina develops, manufactures and distributes premium cell culture reagents intended for culturing of primary cells, such as stem cells. They recently entered into a collaboration with the pharmaceutical company Novo Nordisk to support the development of new cell therapies targeting Parkinson’s disease, heart failure and loss of vision.
With the aim to scale up their production capacity, BioLamina already early on decided to come to Testa Center which was then made possible through financing support from Swelife. By having access to an extensive array of equipment and the special expertise provided at Testa Center, […]
Uppsala-based start-up company Ilya Pharma was also one of the first to run their project at Testa Center and to use its bioprocess equipment.
Ilya Pharma was founded in 2016 based on ground-breaking research from Uppsala University and Swedish University of Agricultural Sciences (SLU) and has today grown to a team of 15 people. The company “has developed its own proprietary technology platform based on the use of living lactic acid bacteria” and are dedicated to “developing the next-generation biological drugs for treating wound in skin and mucosa” (www.ilyapharma.se)
During 2018 the company, as well as their pharmaceutical project, rapidly developed and performed final safety studies and GMP production is under way. Through co-financing from Swelife Ilya Pharma was also given the opportunity to validate its manufacturing process on a large scale and to build valuable industrial knowledge at Testa Center.
Before entering Testa […]